Cingulate

Cingulate P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Cingulate (CING) as of Nov 21, 2026 is -4.72. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -4.40 — a change of 7.22% (lower).

P/FCF

-4.72

YoY

7.22%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Cingulate is 2025 -4.72 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Cingulate was 2024 -4.40 . It decreases by 7.22% lower compared to the previous year.

The Cingulate P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2019
-7.79 USD
Jan 1, 2020
-11.39 USD
Jan 1, 2021
-7.30 USD
Jan 1, 2022
-5.12 USD
Jan 1, 2023
-5.38 USD
Jan 1, 2024
-4.40 USD
Jan 1, 2025
-4.72 USD
The Cingulate P/FCF history
YEARP/FCFYoY
-4.72+7.22%
-4.40-18.24%
-5.38+5.10%
-5.12-29.86%
-7.30-35.87%
-11.39+46.24%
-7.79—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Cingulate is -4.72 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Cingulate changed from -4.40 to -4.72, representing a 7.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Cingulate since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Cingulate with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cingulate

All Key Metrics — Cingulate